Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Income from Continuing Operations (2016 - 2025)

Standard Biotools (LAB) has disclosed Income from Continuing Operations for 16 consecutive years, with 31748000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 44.84% to 31748000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 141583000.0, a 115.03% decrease, with the full-year FY2024 number at 138885000.0, down 237.45% from a year prior.
  • Income from Continuing Operations was 31748000.0 for Q3 2025 at Standard Biotools, down from 17682000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 153196000.0 in Q4 2022 to a low of 76262000.0 in Q1 2022.
  • A 5-year average of 17767736.84 and a median of 20983000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 1724.73% in 2022, then crashed 532.8% in 2024.
  • Standard Biotools' Income from Continuing Operations stood at 9429000.0 in 2021, then surged by 1724.73% to 153196000.0 in 2022, then plummeted by 91.05% to 13709000.0 in 2023, then plummeted by 532.8% to 59332000.0 in 2024, then soared by 46.49% to 31748000.0 in 2025.
  • Per Business Quant, the three most recent readings for LAB's Income from Continuing Operations are 31748000.0 (Q3 2025), 17682000.0 (Q2 2025), and 32821000.0 (Q1 2025).